Payment overview · 2025
General Payments
$5,619.67
90 reported records · 27 companies
Healthcare provider profile · identity verified
Mazhar Elamir
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · JERSEY CITY, NJ · NPI 1972527950
Verified facts
What the public records show
CMS Open Payments records show Mazhar Elamir received $5,619.67 in general payments during 2025 across 90 reported records.
GlaxoSmithKline, LLC. accounted for 73.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 44 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Linzess, Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 262 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 260 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 623 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 230 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 228 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 391 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $4,114.17 | 73.2% | 15 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $157.89 | 2.8% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $151.42 | 2.7% | 7 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $148.38 | 2.6% | 9 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $106.83 | 1.9% | 6 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $99.26 | 1.8% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $90.51 | 1.6% | 5 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $83.03 | 1.5% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $80.30 | 1.4% | 5 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $67.28 | 1.2% | 3 | 2025 |
| 3B Medical, Inc. | Unresolved — no canonical attribution shown | $44.90 | 0.8% | 1 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $44.58 | 0.8% | 2 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $41.94 | 0.8% | 3 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $37.71 | 0.7% | 2 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $37.23 | 0.7% | 2 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $35.74 | 0.6% | 2 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $35.42 | 0.6% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $34.95 | 0.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.58 | 0.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.90 | 0.6% | 2 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $28.11 | 0.5% | 1 | 2025 |
| EVOKE PHARMA, INC. | Unresolved — no canonical attribution shown | $25.29 | 0.5% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $19.25 | 0.3% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $18.15 | 0.3% | 1 | 2025 |
| Forte Bio-Pharma LLC | Unresolved — no canonical attribution shown | $18.13 | 0.3% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.00 | 0.3% | 1 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $15.72 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,900.00 | 1 |
| Food and Beverage | $1,719.67 | 89 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $3,900.00 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $157.89 | 3 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $148.38 | 9 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $108.78 | 6 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $105.39 | 8 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $100.00 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $99.26 | 6 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $74.51 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $67.89 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $67.28 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $61.49 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $61.49 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $53.10 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $50.07 | 3 | 2025 |
Source payment records
|
|||||
| LUNA Normalized: luna |
Device | 3B Medical, Inc. | $44.90 | 1 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $44.58 | 2 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $44.58 | 2 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $44.58 | 2 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $44.58 | 2 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $41.94 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $40.72 | 2 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $37.71 | 2 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $37.23 | 2 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $35.74 | 2 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $35.42 | 2 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $35.42 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $34.95 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $33.58 | 1 | 2025 |
Source payment records
|
|||||
| GLOPERBA Normalized: gloperba |
Drug | SCILEX PHARMACEUTICALS INC. | $32.96 | 2 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $28.11 | 1 | 2025 |
Source payment records
|
|||||
| GIMOTI Normalized: gimoti |
Drug | EVOKE PHARMA, INC. | $25.29 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $18.32 | 1 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| NALOCET Normalized: nalocet |
Drug | Forte Bio-Pharma LLC | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| PROLATE Normalized: prolate |
Drug | Forte Bio-Pharma LLC | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| TANLOR Normalized: tanlor |
Drug | Forte Bio-Pharma LLC | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $16.82 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 89 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 262 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 117 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 623 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
89 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
262 | 50 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
260 | 83 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
132 | 36 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
623 | 139 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
230 | 65 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
117 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
228 | 51 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
391 | 87 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Albuterol Sulfate Hfa | Albuterol Sulfate | 2206 | 514 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1862 | 525 |
| Amlodipine Besylate | Amlodipine Besylate | 1493 | 452 |
| Metformin Hcl | Metformin Hcl | 1238 | 357 |
| Losartan Potassium | Losartan Potassium | 880 | 255 |
| Gabapentin | Gabapentin | 862 | 230 |
| Diclofenac Sodium | Diclofenac Sodium | 807 | 246 |
| Azithromycin | Azithromycin | 767 | 488 |
| Tamsulosin Hcl | Tamsulosin Hcl | 717 | 201 |
| Furosemide | Furosemide | 702 | 189 |
| Fluticasone Propionate | Fluticasone Propionate | 700 | 250 |
| Omeprazole | Omeprazole | 666 | 213 |
| Pantoprazole Sodium | Pantoprazole Sodium | 657 | 218 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 623 | 139 |
| Eliquis | Apixaban | 508 | 101 |
| Montelukast Sodium | Montelukast Sodium | 485 | 145 |
| Ibuprofen | Ibuprofen | 481 | 181 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 471 | 145 |
| Lisinopril | Lisinopril | 459 | 140 |
| Metoprolol Tartrate | Metoprolol Tartrate | 458 | 107 |
| Zolpidem Tartrate | Zolpidem Tartrate | 444 | 93 |
| Levothyroxine Sodium | Levothyroxine Sodium | 418 | 108 |
| Methylprednisolone | Methylprednisolone | 396 | 267 |
| Januvia | Sitagliptin Phosphate | 393 | 105 |
| Ozempic | Semaglutide | 391 | 87 |
| Ventolin Hfa | Albuterol Sulfate | 361 | 99 |
| Clopidogrel | Clopidogrel Bisulfate | 345 | 116 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 339 | 95 |
| Meloxicam | Meloxicam | 331 | 118 |
| Hydrochlorothiazide | Hydrochlorothiazide | 293 | 85 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 288 | 81 |
| Simvastatin | Simvastatin | 282 | 87 |
| Promethazine Hcl | Promethazine Hcl | 278 | 164 |
| Meclizine Hcl | Meclizine Hcl | 274 | 105 |
| Dicyclomine Hcl | Dicyclomine Hcl | 265 | 83 |
| Naproxen | Naproxen | 265 | 113 |
| Linzess | Linaclotide | 262 | 50 |
| Carvedilol | Carvedilol | 261 | 69 |
| Farxiga | Dapagliflozin Propanediol | 260 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 253 | 82 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 249 | 167 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 245 | 99 |
| Famotidine | Famotidine | 243 | 65 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 239 | 69 |
| Mometasone Furoate | Mometasone Furoate | 239 | 88 |
| Alprazolam | Alprazolam | 238 | 55 |
| Finasteride | Finasteride | 237 | 59 |
| Prednisone | Prednisone | 237 | 102 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 235 | 83 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 232 | 92 |
| Jardiance | Empagliflozin | 230 | 65 |
| Trulicity | Dulaglutide | 228 | 51 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 226 | 84 |
| Donepezil Hcl | Donepezil Hcl | 221 | 50 |
| Tramadol Hcl | Tramadol Hcl | 203 | 61 |
| Baclofen | Baclofen | 196 | 66 |
| Sertraline Hcl | Sertraline Hcl | 195 | 37 |
| Fenofibrate | Fenofibrate Nanocrystallized | 188 | 60 |
| Breo Ellipta | Fluticasone/Vilanterol | 185 | 50 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 183 | 51 |
| Lactulose | Lactulose | 181 | 63 |
| Sucralfate | Sucralfate | 177 | 39 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 172 | 46 |
| Hydrocortisone | Hydrocortisone | 172 | 56 |
| Enalapril Maleate | Enalapril Maleate | 169 | 48 |
| Mirtazapine | Mirtazapine | 169 | 54 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 162 | 65 |
| Colchicine | Colchicine | 160 | 47 |
| Potassium Chloride | Potassium Chloride | 160 | 44 |
| Mupirocin | Mupirocin | 155 | 57 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 155 | 35 |
| Ondansetron Odt | Ondansetron | 153 | 62 |
| Glimepiride | Glimepiride | 152 | 48 |
| Glipizide | Glipizide | 151 | 39 |
| Xarelto | Rivaroxaban | 151 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 148 | 49 |
| Trazodone Hcl | Trazodone Hcl | 140 | 39 |
| Alendronate Sodium | Alendronate Sodium | 139 | 29 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 135 | 52 |
| Atenolol | Atenolol | 134 | 30 |
| Allopurinol | Allopurinol | 132 | 34 |
| Symbicort | Budesonide/Formoterol Fumarate | 132 | 36 |
| Valsartan | Valsartan | 132 | 31 |
| Humalog Kwikpen U-100 | Insulin Lispro | 129 | 40 |
| Incruse Ellipta | Umeclidinium Bromide | 128 | 31 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 125 | 84 |
| Levetiracetam | Levetiracetam | 125 | 24 |
| Vascepa | Icosapent Ethyl | 125 | 37 |
| Procto-Med Hc | Hydrocortisone | 122 | 36 |
| Ketoconazole | Ketoconazole | 121 | 31 |
| Nifedipine Er | Nifedipine | 121 | 34 |
| Lidocaine | Lidocaine | 119 | 33 |
| Mounjaro | Tirzepatide | 117 | 35 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 116 | 33 |
| Dexlansoprazole Dr | Dexlansoprazole | 113 | 23 |
| Entresto | Sacubitril/Valsartan | 113 | 21 |
| Clonidine Hcl | Clonidine Hcl | 111 | 25 |
| Megestrol Acetate | Megestrol Acetate | 109 | 38 |
| Latanoprost | Latanoprost | 107 | 15 |
| Spironolactone | Spironolactone | 105 | 38 |
| Pregabalin | Pregabalin | 103 | 28 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 100 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 31 |
| Fenofibrate | Fenofibrate | 97 | 29 |
| Celecoxib | Celecoxib | 96 | 36 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 96 | 24 |
| Myrbetriq | Mirabegron | 95 | 27 |
| Desloratadine | Desloratadine | 92 | 38 |
| Levofloxacin | Levofloxacin | 92 | 69 |
| Creon | Lipase/Protease/Amylase | 89 | 16 |
| Ammonium Lactate | Ammonium Lactate | 87 | 30 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 87 | 35 |
| Loperamide | Loperamide Hcl | 87 | 51 |
| Amoxicillin | Amoxicillin | 86 | 49 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 86 | 24 |
| Fluconazole | Fluconazole | 81 | 41 |
| Ondansetron Hcl | Ondansetron Hcl | 80 | 31 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 80 | 24 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 78 | 25 |
| Divalproex Sodium | Divalproex Sodium | 77 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 77 | 23 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 77 | 26 |
| Metronidazole | Metronidazole | 75 | 52 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 74 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 72 | 25 |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 70 | 35 |
| Risperidone | Risperidone | 70 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 68 | 22 |
| Alcohol Pads | Alcohol Antiseptic Pads | 67 | 21 |
| Clobetasol Propionate | Clobetasol Propionate | 66 | 22 |
| Metoclopramide Hcl | Metoclopramide Hcl | 66 | 17 |
| Novolog Flexpen | Insulin Aspart | 66 | 19 |
| Glipizide Er | Glipizide | 65 | 25 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 65 | 55 |
| Quetiapine Fumarate | Quetiapine Fumarate | 65 | 13 |
| Memantine Hcl | Memantine Hcl | 64 | 13 |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 61 | 28 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 59 | 16 |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 57 | 23 |
| Mupirocin | Mupirocin Calcium | 54 | 23 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 54 | 39 |
| Amitriptyline Hcl | Amitriptyline Hcl | 52 | 15 |
| Clozapine | Clozapine | 51 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 51 | suppressed |
| Cilostazol | Cilostazol | 50 | 14 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 50 | 18 |
| Nebivolol Hcl | Nebivolol Hcl | 50 | 17 |
| Tradjenta | Linagliptin | 50 | 13 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 49 | 15 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 49 | 26 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 49 | 11 |
| Nystatin | Nystatin | 48 | 21 |
| Topiramate | Topiramate | 48 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | 12 |
| Buspirone Hcl | Buspirone Hcl | 47 | 15 |
| Dutasteride | Dutasteride | 47 | 13 |
| Propranolol Hcl | Propranolol Hcl | 47 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | 16 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 45 | 18 |
| Nitroglycerin | Nitroglycerin | 45 | 20 |
| Amiodarone Hcl | Amiodarone Hcl | 44 | 13 |
| Terconazole | Terconazole | 44 | 17 |
| Bydureon Bcise | Exenatide Microspheres | 43 | 11 |
| Insulin Lispro | Insulin Lispro | 43 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | suppressed |
| Acarbose | Acarbose | 42 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 42 | 13 |
| Ezetimibe | Ezetimibe | 42 | 14 |
| Flunisolide | Flunisolide | 42 | 27 |
| Azelastine Hcl | Azelastine Hcl | 41 | 15 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 41 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 41 | 17 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 41 | suppressed |
| Restasis | Cyclosporine | 41 | suppressed |
| Repaglinide | Repaglinide | 40 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 39 | 37 |
| Brilinta | Ticagrelor | 38 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 38 | 14 |
| Spiriva Handihaler | Tiotropium Bromide | 38 | 13 |
| Valacyclovir | Valacyclovir Hcl | 38 | 27 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 37 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | 14 |
| Metformin Hcl Er | Metformin Hcl | 36 | 11 |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 35 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 22 |
| Oxcarbazepine | Oxcarbazepine | 34 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 33 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 33 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | suppressed |
| Cefdinir | Cefdinir | 32 | 28 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 32 | 13 |
| Lorazepam | Lorazepam | 32 | suppressed |
| Ofloxacin | Ofloxacin | 32 | 30 |
| Clotrimazole | Clotrimazole | 31 | 17 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 31 | suppressed |
| Olanzapine | Olanzapine | 31 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 31 | 11 |
| Santyl | Collagenase Clostridium Hist. | 31 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 30 | 14 |
| Nabumetone | Nabumetone | 30 | suppressed |
| Repatha Sureclick | Evolocumab | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | 13 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 30 | 14 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Clonazepam | Clonazepam | 28 | 13 |
| Single Use Swab | Alcohol Antiseptic Pads | 28 | 15 |
| Dupixent Pen | Dupilumab | 27 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 27 | suppressed |
| Felodipine Er | Felodipine | 27 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 27 | 21 |
| Xolair | Omalizumab | 27 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 26 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 26 | suppressed |
| Lacosamide | Lacosamide | 26 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 26 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 25 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 25 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | 13 |
| Alogliptin | Alogliptin Benzoate | 24 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 24 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Methimazole | Methimazole | 24 | suppressed |
| Movantik | Naloxegol Oxalate | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Calcitriol | Calcitriol | 23 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 23 | 15 |
| Dulera | Mometasone/Formoterol | 23 | suppressed |
| Fluocinonide | Fluocinonide | 23 | suppressed |
| Xiidra | Lifitegrast | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 21 | 13 |
| Ibandronate Sodium | Ibandronate Sodium | 21 | suppressed |
| Jublia | Efinaconazole | 21 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 20 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 20 | suppressed |
| Enulose | Lactulose | 20 | suppressed |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 20 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Dexilant | Dexlansoprazole | 19 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 19 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 19 | suppressed |
| Gemtesa | Vibegron | 19 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 19 | 14 |
| True Comfort Safety Pen Needle | Pen Needle, Diabetic, Safety | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 18 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 18 | suppressed |
| Ciclopirox | Ciclopirox | 17 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Haloperidol | Haloperidol | 17 | suppressed |
| Humalog | Insulin Lispro | 17 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 17 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 17 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 16 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Calcium Acetate | Calcium Acetate | 15 | suppressed |
| Constulose | Lactulose | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Percocet | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Proctozone-Hc | Hydrocortisone | 15 | 11 |
| Ramipril | Ramipril | 15 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 15 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 15 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Ibu | Ibuprofen | 14 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Lasix | Furosemide | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Plaquenil | Hydroxychloroquine Sulfate | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Victoza 3-Pak | Liraglutide | 14 | suppressed |
| Cozaar | Losartan Potassium | 13 | suppressed |
| Cyclosporine | Cyclosporine | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Ssd | Silver Sulfadiazine | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Drospirenone-Ethinyl Estradiol | Ethinyl Estradiol/Drospirenone | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Triazolam | Triazolam | 12 | suppressed |
| Admelog Solostar | Insulin Lispro | 11 | suppressed |
| Ambien Cr | Zolpidem Tartrate | 11 | suppressed |
| Comfort Ez Pro Safety Pen Ndl | Pen Needle, Diabetic, Safety | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Tobradex | Tobramycin/Dexamethasone | 11 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Verquvo | Vericiguat | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,619.67 · 90 records | GlaxoSmithKline, LLC. | ACTHAR, AFREZZA, AIRSUPRA, AREXVY, Arikayce, BREZTRI, Brinsupri, CHARTIS CATHETER, CREON, Cologuard Collection Kit, DUPIXENT, FASENRA, GIMOTI, GLOPERBA, INSPIRE, KRYSTEXXA, LINZESS, LUMRYZ, LUNA, MOUNJARO, NALOCET, NUCALA, OPSUMIT, OTEZLA, Ohtuvayre, PROLATE, PULMONX CHARTIS TABLET CONSOLE, PURIFIED CORTROPHIN GEL, REPATHA, SKYCLARYS, SMARTVEST, TANLOR, TEZSPIRE, TRELEGY ELLIPTA, Tyvaso, UPTRAVI, VRAYLAR, WAKIX, Wegovy, XIFAXAN, ZEPBOUND, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE, ZTLido | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error